Cancer-drug company Celgene Corp. said it will pay $7.2 billion for biotech company Receptos Inc. in a bid to move deeper into the multibillion-dollar market for autoimmune diseases.

Celgene Corporation (($CELG)) announced an update on their ongoing clinical study. Celgene Corporation recently completed a Phase 3B study titled ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic versions of its blockbuster blood cancer drug Pomalyst off the market so it could ...

Celgene Corp. is in talks to buy biotechnology company Juno Therapeutics Inc., just days after announcing another major deal to bolster its portfolio of blood-cancer drugs.

Celgene also owns 12.5% of Epizyme , or 3.3 million shares. That position is paying off handsomely since December thanks to positive pipeline news lifting shares from $20 to $30.

Celgene has projected the acquisition will reduce its adjusted EPS (earnings per share) in 2018 by approximately $0.50, but is expected to be incrementally additive to net product sales in 2020.

Celgene, based in Summit, is in the midst of a deal to be acquired by Bristol-Myers Squibb. The acquisition prompted a suit in Delaware Chancery Court last March by a Celgene investor who claimed ...

Celgene Corp. was once a biotech darling, with its stock rising by approximately 150 percent over the past five years. But the shares have fallen off a cliff in recent months, down by nearly 32 ...

Celgene and Juno, though, are advancing JCAR017 to a pivotal clinical study in 2017. Although both areCD19-directed CAR T cell therapies, the safety profile for JCAR017 could be better than JCAR015.

Celgene has enormous growth potential going forward, which could provide the company with significant earnings. The company anticipates that 2020 EPS will reach more than $12.5 per barrel, ...